STAT3 and neoplasm: A novel-CD44 antibody mediated liposomal nanoparticle loaded with anti-IL6R antibody demonstrated specific antimetastatic efficacy in a preclinical mouse model by inhibiting IL-6/STAT3 signaling in CSCs and also reducing the SOX2+ and CD206+ cells in the tumor microenvironment of lung metastasis, thus demonstrating dual inhibitory activity on CSCs themselves and the metastatic niche microenvironment [211].